重新编程细胞命运以实现新的癌症免疫疗法

IF 4 3区医学 Q1 PHARMACOLOGY & PHARMACY Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI:10.1016/j.coph.2022.102312

Eva Hin Wa Leung , Kenneth Joves , Aydolun Petenkaya , Georgina Barham , Thomas G. Henderson , Jie Liang , Constantinos Chronis

{"title":"重新编程细胞命运以实现新的癌症免疫疗法","authors":"Eva Hin Wa Leung , Kenneth Joves , Aydolun Petenkaya , Georgina Barham , Thomas G. Henderson , Jie Liang , Constantinos Chronis","doi":"10.1016/j.coph.2022.102312","DOIUrl":null,"url":null,"abstract":"<div><p>Recent advances in our understanding of host immune and cancer cells interactions have made immunotherapy a prominent choice in cancer treatment. Despite such promise, cell-based immunotherapies remain inapplicable to many patients due to severe limitations in the availability and quality of immune cells isolated from donors. Reprogramming technologies that facilitate the engineering of cell types of interest, are emerging as a putative solution to such challenges. Here we focus on the recent progress being made in reprogramming technologies with respect to the immune system and their potential for clinical applications.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reprogramming cell fates towards novel cancer immunotherapies\",\"authors\":\"Eva Hin Wa Leung , Kenneth Joves , Aydolun Petenkaya , Georgina Barham , Thomas G. Henderson , Jie Liang , Constantinos Chronis\",\"doi\":\"10.1016/j.coph.2022.102312\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Recent advances in our understanding of host immune and cancer cells interactions have made immunotherapy a prominent choice in cancer treatment. Despite such promise, cell-based immunotherapies remain inapplicable to many patients due to severe limitations in the availability and quality of immune cells isolated from donors. Reprogramming technologies that facilitate the engineering of cell types of interest, are emerging as a putative solution to such challenges. Here we focus on the recent progress being made in reprogramming technologies with respect to the immune system and their potential for clinical applications.</p></div>\",\"PeriodicalId\":50603,\"journal\":{\"name\":\"Current Opinion in Pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1471489222001394\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1471489222001394","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

最近我们对宿主免疫和癌细胞相互作用的理解取得了进展，使免疫疗法成为癌症治疗的突出选择。尽管有这样的希望，基于细胞的免疫疗法仍然不适用于许多患者，因为从供体分离的免疫细胞的可用性和质量受到严重限制。重编程技术促进了感兴趣的细胞类型的工程，正在成为解决这些挑战的假定解决方案。在这里，我们将重点介绍免疫系统重编程技术的最新进展及其临床应用潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Reprogramming cell fates towards novel cancer immunotherapies

Recent advances in our understanding of host immune and cancer cells interactions have made immunotherapy a prominent choice in cancer treatment. Despite such promise, cell-based immunotherapies remain inapplicable to many patients due to severe limitations in the availability and quality of immune cells isolated from donors. Reprogramming technologies that facilitate the engineering of cell types of interest, are emerging as a putative solution to such challenges. Here we focus on the recent progress being made in reprogramming technologies with respect to the immune system and their potential for clinical applications.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Opinion in Pharmacology 医学-药学

CiteScore

8.80

自引率

2.50%

发文量

131

审稿时长

4-8 weeks

期刊介绍： Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.

期刊最新文献

Editorial Board Role of specific CDKs in regulating DNA damage repair responses and replication stress Therapeutic innovations for geographic atrophy: A promising horizon Targeting the soluble epoxide hydrolase pathway as a novel therapeutic approach for the treatment of pain Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?